Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Letter: possible association between PPI use and spontaneous bacterial peritonitis.

Alimentary pharmacology & therapeutics·2015

Same author

PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin.

Alimentary pharmacology & therapeutics·2014

Same author

Editorial: healing of refractory reflux oesophagitis--an ongoing unmet clinical need; authors' reply.

Alimentary pharmacology & therapeutics·2014

Same author

Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression.

Alimentary pharmacology & therapeutics·2014

Same author

An evaluation of the potential drug interaction between warfarin and levothyroxine.

Journal of thrombosis and haemostasis : JTH·2014

Same author

Commentary: improving the use of gastroprotective agents among high-risk NSAID users.

Alimentary pharmacology & therapeutics·2013

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.

J R Horn¹, C W Howden

¹Department of Pharmacy, University of Washington, Seattle, WA, USA.

Alimentary Pharmacology & Therapeutics

|November 24, 2005

Summary

Delayed-release proton-pump inhibitors (PPIs) have enteric coatings, causing delayed absorption. While minor formulation differences exist, they do not significantly impact clinical outcomes in patients.

More Related Videos

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

Formation of Dispersible Taohong Siwu Tablets

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jul 17, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

Formation of Dispersible Taohong Siwu Tablets

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Area of Science:

Pharmacology
Gastroenterology

Background:

Proton-pump inhibitors (PPIs) are acid-labile and require enteric coating for oral administration to prevent stomach degradation.
Enteric coating leads to delayed absorption and onset of action for PPIs.

Purpose of the Study:

To review similarities and differences between various delayed-release proton-pump inhibitor formulations.
To evaluate the impact of formulation differences on pharmacokinetics and pharmacodynamics.

Main Methods:

Review of existing literature on delayed-release proton-pump inhibitor formulations.
Analysis of pharmacokinetic and pharmacodynamic data for different PPI formulations.

Main Results:

Delayed-release PPIs, including omeprazole and lansoprazole, show formulation-based pharmacokinetic differences, mainly in initial bioavailability.
Some formulations, like omeprazole suspended in sodium bicarbonate for tube administration, may have impaired absorption and reduced antisecretory effects.
Few significant differences exist in pharmacodynamic effects during chronic administration among delayed-release PPIs.

Conclusions:

Minor pharmacokinetic and pharmacodynamic differences among delayed-release PPI formulations do not result in meaningful differences in clinical outcomes.
Formulation choices may offer convenience but do not fundamentally alter therapeutic efficacy in the long term.